

## Appendix E – Evidence Profile for all outcomes assessed.

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	iPACK + sACB	sACB	Relative (95% CI)	Absolute (95% CI)		

***iPACK + ACB versus ACB in presence of LIA*****Rest pain at 0 hours (PACU) (cm)**

4	randomised trials	not serious	not serious	not serious	serious <sup>b</sup>	none	137	136	Not Applicable	MD <b>0.02 lower</b> (0.12 lower to 0.07 higher)	⊕⊕⊕○ MODERATE	IMPORTANT
---	-------------------	-------------	-------------	-------------	----------------------	------	-----	-----	----------------	---	------------------	-----------

**Rest pain at 6 hours (cm)**

4	randomised trials	not serious	not serious	not serious	serious <sup>b</sup>	none	137	136	Not Applicable	MD <b>0.41 lower</b> (0.84 lower to 0.02 higher)	⊕⊕⊕○ MODERATE	CRITICAL
---	-------------------	-------------	-------------	-------------	----------------------	------	-----	-----	----------------	---	------------------	----------

**Rest pain at 12 hours (cm)**

4	randomised trials	not serious	not serious	not serious	serious <sup>b</sup>	none	137	136	Not Applicable	MD <b>0.41 lower</b> (0.90 lower to 0.08 higher)	⊕⊕⊕○ MODERATE	IMPORTANT
---	-------------------	-------------	-------------	-------------	----------------------	------	-----	-----	----------------	---	------------------	-----------

**Rest pain at 24 hours (cm)**

4	randomised trials	not serious	not serious	not serious	not serious	none	137	136	Not Applicable	MD <b>0.19 lower</b> (0.52 lower to 0.13 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
---	-------------------	-------------	-------------	-------------	-------------	------	-----	-----	----------------	---	--------------	-----------

**Post-operative function**

3	randomised trials	not serious	serious <sup>a</sup>	not serious	serious <sup>b</sup>	none	129	128	Not Applicable	Log(OR) <b>0.90 lower</b> (2.65 lower to 0.84 higher)	⊕⊕○○ LOW	IMPORTANT
---	-------------------	-------------	----------------------	-------------	----------------------	------	-----	-----	----------------	--	-------------	-----------

**Morphine consumption at 24 hours (mg)**

4	randomised trials	not serious	serious <sup>a</sup>	not serious	serious <sup>b</sup>	none	137	136	Not Applicable	MD <b>4.17 lower</b> (9.85 lower to 1.51 higher)	⊕⊕○○ LOW	IMPORTANT
---	-------------------	-------------	----------------------	-------------	----------------------	------	-----	-----	----------------	---	-------------	-----------

***iPACK + ACB versus ACB in absence of LIA*****Rest pain at 0 hours (PACU) (cm)**

5	randomized trials	not serious	serious <sup>a</sup>	not serious	serious <sup>b</sup>	none	173	172	Not Applicable	MD <b>0.87 lower</b> (1.76 lower to 0.02 higher)	⊕⊕○○ LOW	IMPORTANT
---	-------------------	-------------	----------------------	-------------	----------------------	------	-----	-----	----------------	---	-------------	-----------

## Rest pain at 6 hours (cm)

8	randomized trials	not serious	serious <sup>a</sup>	not serious	not serious	none	316	315	Not Applicable	MD 1.33 lower (1.58 lower to 1.08 lower)	⊕⊕⊕○ MODERATE	CRITICAL
---	-------------------	-------------	----------------------	-------------	-------------	------	-----	-----	----------------	---	------------------	----------

## Rest pain at 12 hours (cm)

6	randomized trials	not serious	serious <sup>a</sup>	not serious	not serious	none	250	249	Not Applicable	MD 0.98 lower (1.79 lower to 0.17 lower)	⊕⊕⊕○ MODERATE	IMPORTANT
---	-------------------	-------------	----------------------	-------------	-------------	------	-----	-----	----------------	---	------------------	-----------

## Rest pain at 24 hours (cm)

10	randomized trials	not serious	serious <sup>a</sup>	not serious	not serious	none	234	234	Not Applicable	MD 0.69 lower (1.18 lower to 0.20 lower)	⊕⊕⊕○ MODERATE	IMPORTANT
----	-------------------	-------------	----------------------	-------------	-------------	------	-----	-----	----------------	---	------------------	-----------

## Morphine consumption at 24 hours (mg)

3	randomized trials	not serious	not serious	not serious	serious <sup>b</sup>	none	124	122	Not Applicable	MD 1.21 lower (-9.71 lower to 7.29 higher)	⊕⊕⊕○ MODERATE	IMPORTANT
---	-------------------	-------------	-------------	-------------	----------------------	------	-----	-----	----------------	---	------------------	-----------

## Post-operative function

9	randomized trials	not serious	serious <sup>a</sup>	not serious	not serious	none	349	347	Not Applicable	Log(OR) 1.88 higher (0.45 higher to 2.11 higher)	⊕⊕⊕○ MODERATE	IMPORTANT
---	-------------------	-------------	----------------------	-------------	-------------	------	-----	-----	----------------	---	------------------	-----------

## Opioid related side effects

6	randomised trials	not serious	not serious	not serious	not serious	none	17/200 (8.5%)	32/198 (16.2%)	OR 0.43 (0.26 to 1.02)	72 fewer per 1,000 (from 114 fewer to 3 more)	⊕⊕⊕⊕ HIGH	CRITICAL
---	-------------------	-------------	-------------	-------------	-------------	------	---------------	----------------	---------------------------	--	--------------	----------

## Block-related complications

6	randomised trials	not serious	not serious	not serious	not serious	none	0/190 (0.0%)	0/190 (0.0%)	Not applicable	Not Applicable	⊕⊕⊕⊕ HIGH	CRITICAL
---	-------------------	-------------	-------------	-------------	-------------	------	--------------	--------------	----------------	----------------	--------------	----------

CI: Confidence interval; MD: Mean difference; OR: Odds ratio; ACB: adductor canal block; iPACK: infiltration between popliteal artery and posterior capsule of knee; CM: centimeter.

## Explanations

- a. Heterogeneity > 50%.
- b. Lower and upper bound of confidence interval change direction of benefit.